3869 |
Optimal Endovascular Treatment with Drug Eluting Stent |
Young-Guk Ko |
Apr. 27. 19 |
3868 |
Favorable Neurological Outcome After Percutaneous LAAO |
Jung-Sun Kim |
Apr. 27. 19 |
3867 |
Why and How? The Optimal Role of New Generation Drug Coated Balloon at Lower Limbs Treatment |
Jen-Kuang Lee |
Apr. 27. 19 |
3866 |
Who Are the Candidates for Renal Denervation? |
Wojciech Wojakowski |
Apr. 27. 19 |
3865 |
Re-defining the Role of Ticagrelor for Long-term DAPT ; How to Apply PEGASUS TIMI-54 to Real World Practice |
Soon Jun Hong |
Apr. 27. 19 |
3864 |
Changing Practice of ACS Treatment Based on PLATO & Guideline Recommendation; Insight from One-year Real-World Registry |
Kyounghoon Lee |
Apr. 27. 19 |
3863 |
Residual Ischemic Risk and Benefit of Prolonged DAPT; Update Latest Clinical Trials |
Jin Joo Park |
Apr. 27. 19 |
3862 |
Renal Denervation Works: Why Can\'t We Prove It? |
James R. Margolis |
Apr. 27. 19 |
3861 |
Durability of Balloon-Expandable Transcatheter Heart Valve |
Alain G. Cribier |
Apr. 27. 19 |
3860 |
Sapien 3 THV with Future Coronary Access |
Alan C. Yeung |
Apr. 27. 19 |